IL317447A - Antibody drug conjugates - Google Patents
Antibody drug conjugatesInfo
- Publication number
- IL317447A IL317447A IL317447A IL31744724A IL317447A IL 317447 A IL317447 A IL 317447A IL 317447 A IL317447 A IL 317447A IL 31744724 A IL31744724 A IL 31744724A IL 317447 A IL317447 A IL 317447A
- Authority
- IL
- Israel
- Prior art keywords
- drug conjugates
- antibody drug
- antibody
- conjugates
- drug
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 title 1
- 229940049595 antibody-drug conjugate Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
- C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022097834 | 2022-06-09 | ||
| PCT/CN2023/099148 WO2023237050A1 (en) | 2022-06-09 | 2023-06-08 | Antibody drug conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL317447A true IL317447A (en) | 2025-02-01 |
Family
ID=89117517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL317447A IL317447A (en) | 2022-06-09 | 2023-06-08 | Antibody drug conjugates |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250099607A1 (en) |
| EP (1) | EP4536666A4 (en) |
| JP (1) | JP2025519421A (en) |
| KR (1) | KR20250020660A (en) |
| CN (1) | CN119317630A (en) |
| AU (1) | AU2023283560A1 (en) |
| CA (1) | CA3258612A1 (en) |
| CL (1) | CL2024003768A1 (en) |
| CO (1) | CO2025000056A2 (en) |
| IL (1) | IL317447A (en) |
| MX (1) | MX2024015179A (en) |
| WO (1) | WO2023237050A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12605459B2 (en) | 2020-07-13 | 2026-04-21 | Regeneron Pharmaceuticals, Inc. | Protein-drug conjugates comprising camptothecin analogs and methods of use thereof |
| WO2024138000A1 (en) * | 2022-12-21 | 2024-06-27 | Regeneron Pharmaceuticals, Inc. | Prodrugs of topoisomerase i inhibitor for adc conjugations and methods of use thereof |
| FI131754B1 (en) * | 2023-03-13 | 2025-11-11 | Glykos Finland Oy | ANTIBODY SEXATECAN CONJUGATE |
| AR134651A1 (en) * | 2023-12-13 | 2026-02-04 | Beigene Ltd | ANTIBODY-DRUG CONJUGATE PLATFORMS |
| TW202543679A (en) | 2023-12-29 | 2025-11-16 | 大陸商杭州尚健生物技術有限公司 | An immune conjugate and use thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG194567A1 (en) * | 2011-04-21 | 2013-12-30 | Seattle Genetics Inc | Novel binder-drug conjugates (adcs) and their use |
| US10195288B2 (en) * | 2012-10-11 | 2019-02-05 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate |
| EP2910573B1 (en) * | 2012-10-19 | 2020-02-19 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate produced by binding through linker having hydrophilic structure |
| TWI871999B (en) * | 2014-04-10 | 2025-02-01 | 日商第一三共股份有限公司 | Anti-her3 antibody drug conjugate |
| US20170014524A1 (en) * | 2015-07-15 | 2017-01-19 | The California Institute For Biomedical Research | Auristatin-antibody conjugates and uses thereof |
| SG11201906554RA (en) * | 2017-01-17 | 2019-08-27 | Daiichi Sankyo Co Ltd | Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate |
| CN111065416B (en) * | 2017-06-21 | 2024-09-13 | 芬兰吉利科斯有限公司 | Hydrophilic linkers and conjugates thereof |
| UA130338C2 (en) * | 2018-09-26 | 2026-01-28 | Джянгсу Хенгруй Медісін Ко., Лтд. | LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, METHOD FOR ITS PREPARATION AND ITS USE |
| JP7821733B2 (en) * | 2020-01-22 | 2026-02-27 | 上海森輝医薬有限公司 | Drug conjugate of eribulin derivative, its preparation method and medical application |
| US20230101735A1 (en) * | 2020-01-22 | 2023-03-30 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-trop-2 antidody-exatecan analog conjugate and medical use thereof |
| CN114845740B (en) * | 2020-01-31 | 2026-06-02 | 先天制药公司 | Cancer treatment |
| CA3175048A1 (en) * | 2020-03-25 | 2021-09-30 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Preparation method for antibody medicament conjugate |
| WO2021190586A1 (en) * | 2020-03-25 | 2021-09-30 | 江苏恒瑞医药股份有限公司 | B7h3 antibody-exatecan analogue conjugate and pharmaceutical use thereof |
| WO2021190564A1 (en) * | 2020-03-26 | 2021-09-30 | 上海翰森生物医药科技有限公司 | Antibody-drug conjugate and medical use thereof |
| EP4227310A4 (en) * | 2020-10-12 | 2024-11-06 | Sichuan Baili Pharmaceutical Co. Ltd. | CAMPTOTHECIN DERIVATIVE AND LIGAND-DRUG CONJUGATE THEREOF |
| CN116133694B (en) * | 2020-10-14 | 2026-03-06 | 苏州盛迪亚生物医药有限公司 | Anti-HER3 antibodies and anti-HER3 antibody-drug conjugates and their pharmaceutical uses |
| JP2024501121A (en) * | 2020-11-25 | 2024-01-11 | イナート・ファルマ・ソシエテ・アノニム | cancer treatment |
| CN113816990B (en) * | 2021-03-22 | 2023-08-22 | 联宁(苏州)生物制药有限公司 | Modified amino acids and their use in ADCs |
| US12533419B2 (en) * | 2021-07-19 | 2026-01-27 | Mabplex International Co., Ltd. | Antibody drug conjugate loaded with binary toxins and its application |
-
2023
- 2023-06-08 JP JP2024571372A patent/JP2025519421A/en active Pending
- 2023-06-08 EP EP23819214.0A patent/EP4536666A4/en active Pending
- 2023-06-08 CN CN202380044462.0A patent/CN119317630A/en active Pending
- 2023-06-08 CA CA3258612A patent/CA3258612A1/en active Pending
- 2023-06-08 KR KR1020257000809A patent/KR20250020660A/en active Pending
- 2023-06-08 IL IL317447A patent/IL317447A/en unknown
- 2023-06-08 WO PCT/CN2023/099148 patent/WO2023237050A1/en not_active Ceased
- 2023-06-08 AU AU2023283560A patent/AU2023283560A1/en active Pending
-
2024
- 2024-12-06 US US18/971,958 patent/US20250099607A1/en active Pending
- 2024-12-06 MX MX2024015179A patent/MX2024015179A/en unknown
- 2024-12-09 CL CL2024003768A patent/CL2024003768A1/en unknown
-
2025
- 2025-01-07 CO CONC2025/0000056A patent/CO2025000056A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20250020660A (en) | 2025-02-11 |
| JP2025519421A (en) | 2025-06-26 |
| US20250099607A1 (en) | 2025-03-27 |
| WO2023237050A1 (en) | 2023-12-14 |
| CN119317630A (en) | 2025-01-14 |
| CA3258612A1 (en) | 2023-12-14 |
| MX2024015179A (en) | 2025-02-10 |
| AU2023283560A1 (en) | 2025-01-23 |
| CO2025000056A2 (en) | 2025-01-23 |
| EP4536666A1 (en) | 2025-04-16 |
| CL2024003768A1 (en) | 2025-03-28 |
| EP4536666A4 (en) | 2026-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL313805A (en) | Antibody drug conjugates | |
| TWI925817B (en) | Antibody drug conjugates | |
| AU2021374958A9 (en) | Antibody drug conjugates | |
| PL4217398T3 (en) | Anti-c-met antibody drug conjugates | |
| IL299362A (en) | Antibody-drug conjugates comprising anti-b7-h3 antibodies | |
| CA3247730A1 (en) | Hydrophilic linkers for antibody drug conjugates | |
| PT3941946T (en) | Claudin-6 antibodies and drug conjugates | |
| IL311231A (en) | Linkers for use in antibody drug conjugates | |
| IL308795A (en) | Anthracycline antibody conjugates | |
| ZA202211123B (en) | Drug antibody conjugates | |
| IL308812A (en) | Neodegrader-anti-cd33 antibody conjugates | |
| IL316653A (en) | Antibody drug conjugates | |
| IL314622A (en) | Humanized antibodies against nectin-2 and drug conjugates thereof | |
| IL321698A (en) | B7h3 antibody drug conjugates | |
| SMT202400364T1 (en) | Humanized anti-prostate-specific membrane antigen (psma) antibody drug conjugates | |
| EP4130036A4 (en) | Antibody drug conjugate | |
| IL309048A (en) | Anti-egfrviii antibody drug conjugates and uses thereof | |
| IL326788A (en) | Anti-Duple antibody conjugates | |
| HK40116669A (en) | Antibody drug conjugates | |
| IL317285A (en) | Anti-cd19 antibody drug conjugates | |
| CA3288355A1 (en) | Antibody drug conjugates | |
| CA3278026A1 (en) | Antibody drug conjugates | |
| CA3303200A1 (en) | Anti-doppel antibody drug conjugates | |
| HK40124190A (en) | Antibody drug conjugates | |
| HK40117329A (en) | Antibody drug conjugates |